MDACC Study No:2013-0656 ( NCT No: NCT01994837)
Title:A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)
Principal Investigator:Marina Konopleva
Treatment Agent:ABT-199
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ABT-199 can help to
control AML. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:ABT-199
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:AbbVie
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults